Quantcast

Latest CytRx Stories

2014-07-09 20:22:38

NEW YORK, July 9, 2014 /PRNewswire/ -- Levi & Korsinsky, LLP is investigating CytRx Corporation (NASDAQ: CYTR) in connection with possible claims of breaches of fiduciary duty by the board of directors of the Company. http://photos.prnewswire.com/prnvar/20120409/MM84375LOGO To get more information, click here: http://zlk.9nl.com/cytrx. There is no cost or obligation to you. If you own common stock in CytRx and wish to obtain additional information, please contact Eduard...

2014-05-09 20:22:54

NEW YORK, May 9, 2014 /PRNewswire/ -- Pomerantz LLP announces the filing of a class action lawsuit against CytRx Corporation ("CytRx" or the "Company")(NASDAQ: CYTR) and certain of its officers. The class action, filed in United States District Court, Central District of California and docketed under 14-cv-02689, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired securities of CytRX between November 22, 2013 and March 13, 2014, both...

2014-04-28 08:26:37

LONDON, April 28, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Non-Small Cell Lung Cancer Global Clinical Trials Review, H1, 2014http://www.reportbuyer.com/pharma_healthcare/research_rd/clinical_trials/non_small_cell_lung_cancer_global_clinical_trials_review.html Non-Small Cell Lung Cancer Global Clinical Trials Review, H1, 2014SummaryGlobalData's clinical trial report, "Non-Small Cell Lung Cancer Global Clinical Trials Review, H1, 2014" provides data...

2014-03-24 16:24:59

In the news release, Attention CytRx Corporation Investors: CytRx Misled Investors According to a Recently Filed Class Action, issued 21-Mar-2014 by Robbins Arroyo LLP over PR Newswire, we are advised by the company that the third paragraph should read that Steven A. Kriegsman sold $2.1 million of Galena Biopharma, Inc. shares, not CytRx shares as originally issued. The complete, corrected release follows: Attention CytRx Corporation Investors: CytRx Misled Investors According to a...

2014-03-21 20:21:48

SAN DIEGO and LOS ANGELES, March 21, 2014 /PRNewswire/ -- Shareholder rights law firm Robbins Arroyo LLP announces that an investor of CytRx Corporation (NASDAQ: CYTR) has filed a federal securities fraud class action complaint in the U.S. District Court for the Central District of California. The complaint alleges that the company and certain of its officers and directors violated the Securities and Exchange Act of 1934 between November 22, 2013 and March 13, 2014, including the...

2014-02-03 08:26:48

SAN DIEGO, Feb. 3, 2014 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento) a late-stage clinical oncology company developing new treatments for cancer and associated pain, today announced the addition of Clinical Oncologist Daniel Levitt, M.D., Ph.D., as a member to its Board of Directors. He currently serves as Executive Vice President and Chief Medical Officer of CytRx Corporation. "Daniel's proven expertise overseeing the successful development of major oncology...

2014-01-06 08:26:43

Editor Note: For more information about this release, please scroll to bottom. NEW YORK, January 6, 2014 /PRNewswire/ -- Today, Analysts' Corner announced new research reports highlighting CytRx Corporation (NASDAQ: CYTR), Quidel Corp. (NASDAQ: QDEL), Repligen Corporation (NASDAQ: RGEN), Intrexon Corporation (NYSE: XON), and Acacia Research Corporation (NASDAQ: ACTG). Today's readers may access these reports free of charge - including full price targets, industry analysis and...

2013-08-01 23:22:59

MarketResearchReports.Biz announces addition of new report “Small-Cell Lung Cancer - Pipeline Review, H2 2013” to its database. Visit - http://www.marketresearchreports.biz/analysis-details/small-cell-lung-cancer-pipeline-review-h2-2013. Albany, New York (PRWEB) August 01, 2013 Global Markets Directs, Small-Cell Lung Cancer - Pipeline Review, H2 2013, provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for...

2009-11-12 08:00:00

CAMBRIDGE, Mass., Nov. 12 /PRNewswire/ -- Cequent Pharmaceuticals, a pioneer in the development of novel products to deliver RNAi-based treatments to prevent and treat human disease, has announced that it has filed its first IND (investigational new drug) application with the U.S. Food and Drug Administration (FDA). CEQ508, an orally administered tkRNAi drug candidate, targets beta-catenin, a key oncogene implicated in the formation of colonic polyps and in the progression of polyps to...


Word of the Day
grass-comber
  • A landsman who is making his first voyage at sea; a novice who enters naval service from rural life.
According to the OED, a grass-comber is also 'a sailor's term for one who has been a farm-labourer.'